NI200900031A - N-METHYLAMINOMETHYL ISOINDOL COMPOSITIONS AND COMPOSITIONS THAT INCLUDE THEM AND METHODS FOR USING THEM. - Google Patents
N-METHYLAMINOMETHYL ISOINDOL COMPOSITIONS AND COMPOSITIONS THAT INCLUDE THEM AND METHODS FOR USING THEM.Info
- Publication number
- NI200900031A NI200900031A NI200900031A NI200900031A NI200900031A NI 200900031 A NI200900031 A NI 200900031A NI 200900031 A NI200900031 A NI 200900031A NI 200900031 A NI200900031 A NI 200900031A NI 200900031 A NI200900031 A NI 200900031A
- Authority
- NI
- Nicaragua
- Prior art keywords
- compositions
- methylaminomethyl
- methods
- isoindol
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Abstract
La invención se refiere a compuestos de N-metilaminometil-isoindolina, y sales farmacéuticamente aceptables, solvatos, estereoisómeros, y profármacos de los mismos. Se describen métodos de uso, y composiciones farmacéuticas de estos compuestos.The invention relates to N-methylaminomethyl-isoindoline compounds, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are described.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84522706P | 2006-09-15 | 2006-09-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
NI200900031A true NI200900031A (en) | 2010-02-01 |
Family
ID=38983295
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NI200900031A NI200900031A (en) | 2006-09-15 | 2009-03-13 | N-METHYLAMINOMETHYL ISOINDOL COMPOSITIONS AND COMPOSITIONS THAT INCLUDE THEM AND METHODS FOR USING THEM. |
Country Status (30)
Country | Link |
---|---|
US (2) | US8648096B2 (en) |
EP (1) | EP2076260B1 (en) |
JP (1) | JP5567339B2 (en) |
KR (1) | KR20090050107A (en) |
CN (2) | CN103382197A (en) |
AR (1) | AR062875A1 (en) |
AT (1) | ATE502634T1 (en) |
CA (1) | CA2663376C (en) |
CL (1) | CL2007002670A1 (en) |
CO (1) | CO6180446A2 (en) |
CR (1) | CR10696A (en) |
CY (1) | CY1112558T1 (en) |
DE (1) | DE602007013436D1 (en) |
DK (1) | DK2076260T3 (en) |
ES (1) | ES2361584T3 (en) |
HR (1) | HRP20110261T1 (en) |
IL (1) | IL197566A0 (en) |
MX (1) | MX2009002666A (en) |
NI (1) | NI200900031A (en) |
NZ (1) | NZ575689A (en) |
PE (1) | PE20080832A1 (en) |
PL (1) | PL2076260T3 (en) |
PT (1) | PT2076260E (en) |
RS (1) | RS51725B (en) |
RU (1) | RU2009114159A (en) |
SI (1) | SI2076260T1 (en) |
TW (1) | TW200819435A (en) |
UA (1) | UA95975C2 (en) |
WO (1) | WO2008033567A1 (en) |
ZA (1) | ZA200901852B (en) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0514865A (en) * | 2004-09-03 | 2008-06-24 | Celgene Corp | process for preparing a compound |
ES2402204T3 (en) | 2005-06-30 | 2013-04-29 | Celgene Corporation | Procedures for the preparation of 4-amino-2- (2,6-dioxopiperidin-3-yl) isoindoline-1,3-dione compounds |
CN103382197A (en) * | 2006-09-15 | 2013-11-06 | 细胞基因公司 | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same |
US20100160368A1 (en) | 2008-08-18 | 2010-06-24 | Gregory Jefferson J | Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy |
SG195613A1 (en) * | 2008-10-29 | 2013-12-30 | Celgene Corp | Isoindoline compounds for use in the treatment of cancer |
US20110021555A1 (en) * | 2008-12-19 | 2011-01-27 | Graceway Pharmaceuticals, Llc | Lower dosage strength imiquimod formulations and shorter dosing regimens for treating actinic keratoses |
AU2010274097B2 (en) * | 2009-07-13 | 2016-06-16 | Medicis Pharmaceutical Corporation | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
EP3202460B1 (en) | 2010-02-11 | 2019-06-12 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
WO2012135299A1 (en) | 2011-03-28 | 2012-10-04 | Deuteria Pharmaceuticals Inc | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
JP6359563B2 (en) | 2013-01-14 | 2018-07-18 | デュートルクス・リミテッド・ライアビリティ・カンパニーDeuteRx, LLC | 3- (5-substituted-4-oxoquinazolin-3 (4H) -yl) -3-deuteropiperidine-2,6-dione derivatives |
BR112015022785A2 (en) | 2013-03-14 | 2017-07-18 | Epizyme Inc | compound; pharmaceutical composition; packaged pharmaceutical kit or article; method of inhibiting an arginine methyl transferase (rmt); method of modulating gene expression; transcription modulation method; and method of treating an rmt-mediated disorder |
WO2014153172A1 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
EP2970134B1 (en) | 2013-03-14 | 2018-02-28 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
US9765035B2 (en) | 2013-03-14 | 2017-09-19 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
WO2014152833A1 (en) | 2013-03-14 | 2014-09-25 | Deuterx, Llc | 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
WO2014153214A1 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Arginine methyl transferase inhibtors and uses thereof |
US9023883B2 (en) | 2013-03-14 | 2015-05-05 | Epizyme, Inc. | PRMT1 inhibitors and uses thereof |
US20160031839A1 (en) | 2013-03-14 | 2016-02-04 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
US9346761B2 (en) | 2013-03-14 | 2016-05-24 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
EP2970181B1 (en) | 2013-03-14 | 2017-06-07 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
US9120757B2 (en) | 2013-03-14 | 2015-09-01 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
BR112015026006B1 (en) | 2013-04-17 | 2022-10-18 | Signal Pharmaceuticals, Llc | USE OF A COMPOUND IN COMBINATION WITH AN IMID® IMMUNOMODULATING DRUG FOR THE TREATMENT OR PREVENTION OF CANCER, PHARMACEUTICAL COMPOSITION AND KIT COMPRISING SUCH COMPOUNDS |
UA117141C2 (en) | 2013-10-08 | 2018-06-25 | Селджин Корпорейшн | Formulations of (s)-3-(4-((4-(morpholinomethyl)benzyloxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
EA037738B1 (en) | 2014-08-07 | 2021-05-17 | Калитера Байосайенсиз, Инк. | Crystal forms of glutaminase inhibitors |
DK3643709T3 (en) * | 2014-10-30 | 2021-12-20 | Kangpu Biopharmaceuticals Inc | ISOINDOLINE DERIVATIVE, INTERMEDIATE PRODUCT, METHOD OF MANUFACTURE, PHARMACEUTICAL COMPOSITION AND USE |
US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
WO2017040376A1 (en) * | 2015-08-31 | 2017-03-09 | The University Of Toledo | Potent phthalate inhibitors of aspartate n-acetyltransferase and selective aspartate pathway inhibitors |
US10011566B2 (en) | 2015-12-15 | 2018-07-03 | Astrazeneca Ab | Compounds |
EP3440082A1 (en) * | 2016-04-06 | 2019-02-13 | The Regents of The University of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
EP3454862A4 (en) | 2016-05-10 | 2020-02-12 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
CN109641874A (en) | 2016-05-10 | 2019-04-16 | C4医药公司 | C for target protein degradation3The glutarimide degron body of carbon connection |
SG11201903483VA (en) | 2016-10-28 | 2019-05-30 | Icahn School Med Mount Sinai | Compositions and methods for treating ezh2-mediated cancer |
US11541051B2 (en) | 2016-12-08 | 2023-01-03 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating CDK4/6-mediated cancer |
EP3638661A1 (en) | 2017-06-14 | 2020-04-22 | Astrazeneca AB | 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators |
WO2018237026A1 (en) | 2017-06-20 | 2018-12-27 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
CN111278815B (en) | 2017-09-04 | 2024-03-08 | C4医药公司 | Glutarimide |
CN111315735B (en) | 2017-09-04 | 2024-03-08 | C4医药公司 | Dihydrobenzimidazolone |
EP3679028A1 (en) | 2017-09-04 | 2020-07-15 | C4 Therapeutics, Inc. | Dihydroquinolinones |
EP3710002A4 (en) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | Degraders and degrons for targeted protein degradation |
AU2019231689A1 (en) * | 2018-03-06 | 2020-09-24 | Icahn School Of Medicine At Mount Sinai | Serine threonine kinase (AKT) degradation / disruption compounds and methods of use |
EP3773576A4 (en) | 2018-03-26 | 2021-12-29 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
WO2019204354A1 (en) | 2018-04-16 | 2019-10-24 | C4 Therapeutics, Inc. | Spirocyclic compounds |
HUE064340T2 (en) * | 2018-04-23 | 2024-03-28 | Celgene Corp | Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma |
EP3578561A1 (en) | 2018-06-04 | 2019-12-11 | F. Hoffmann-La Roche AG | Spiro compounds |
WO2020210630A1 (en) | 2019-04-12 | 2020-10-15 | C4 Therapeutics, Inc. | Tricyclic degraders of ikaros and aiolos |
EP4048279A1 (en) | 2019-10-21 | 2022-08-31 | Celgene Corporation | Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione |
AU2020372333A1 (en) * | 2019-10-21 | 2022-04-28 | Celgene Corporation | Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-Dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione |
CN110746400B (en) * | 2019-11-07 | 2021-12-17 | 郑州大学 | Androgen receptor targeted fluorescent probe and preparation method thereof |
JP2024504932A (en) | 2021-01-13 | 2024-02-02 | モンテ ローザ セラピューティクス, インコーポレイテッド | isoindolinone compound |
CN115504963A (en) * | 2021-06-22 | 2022-12-23 | 苏州开拓药业股份有限公司 | C-Myc protein degradation agent |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
US6281230B1 (en) * | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
TR200101501T2 (en) * | 1998-03-16 | 2002-06-21 | Celgene Corporation | 2- (2,6-dioxopiperidin-3-yl) isoindoline derivatives, their preparation and use as inhibitors of inflammatory cytokines. |
US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
EP1569907B1 (en) * | 2002-12-13 | 2016-03-09 | YM BioSciences Australia Pty Ltd | Nicotinamide-based kinase inhibitors |
US20050143344A1 (en) * | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
ES2402204T3 (en) * | 2005-06-30 | 2013-04-29 | Celgene Corporation | Procedures for the preparation of 4-amino-2- (2,6-dioxopiperidin-3-yl) isoindoline-1,3-dione compounds |
CN103382197A (en) * | 2006-09-15 | 2013-11-06 | 细胞基因公司 | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same |
-
2007
- 2007-09-14 CN CN2013102182141A patent/CN103382197A/en active Pending
- 2007-09-14 CA CA2663376A patent/CA2663376C/en active Active
- 2007-09-14 ZA ZA200901852A patent/ZA200901852B/en unknown
- 2007-09-14 KR KR1020097006986A patent/KR20090050107A/en not_active Application Discontinuation
- 2007-09-14 CN CNA2007800424312A patent/CN101534820A/en active Pending
- 2007-09-14 CL CL200702670A patent/CL2007002670A1/en unknown
- 2007-09-14 ES ES07838415T patent/ES2361584T3/en active Active
- 2007-09-14 NZ NZ575689A patent/NZ575689A/en not_active IP Right Cessation
- 2007-09-14 UA UAA200903664A patent/UA95975C2/en unknown
- 2007-09-14 TW TW096134612A patent/TW200819435A/en unknown
- 2007-09-14 RS RS20110258A patent/RS51725B/en unknown
- 2007-09-14 DE DE602007013436T patent/DE602007013436D1/en active Active
- 2007-09-14 WO PCT/US2007/020201 patent/WO2008033567A1/en active Application Filing
- 2007-09-14 PL PL07838415T patent/PL2076260T3/en unknown
- 2007-09-14 EP EP07838415A patent/EP2076260B1/en active Active
- 2007-09-14 US US11/901,291 patent/US8648096B2/en active Active
- 2007-09-14 SI SI200730569T patent/SI2076260T1/en unknown
- 2007-09-14 PT PT07838415T patent/PT2076260E/en unknown
- 2007-09-14 MX MX2009002666A patent/MX2009002666A/en active IP Right Grant
- 2007-09-14 DK DK07838415.3T patent/DK2076260T3/en active
- 2007-09-14 RU RU2009114159/15A patent/RU2009114159A/en not_active Application Discontinuation
- 2007-09-14 AT AT07838415T patent/ATE502634T1/en active
- 2007-09-14 JP JP2009528337A patent/JP5567339B2/en active Active
- 2007-09-17 AR ARP070104112A patent/AR062875A1/en unknown
- 2007-09-17 PE PE2007001253A patent/PE20080832A1/en not_active Application Discontinuation
-
2009
- 2009-03-12 IL IL197566A patent/IL197566A0/en unknown
- 2009-03-13 NI NI200900031A patent/NI200900031A/en unknown
- 2009-03-30 CR CR10696A patent/CR10696A/en not_active Application Discontinuation
- 2009-04-03 CO CO09034806A patent/CO6180446A2/en not_active Application Discontinuation
-
2011
- 2011-04-12 HR HR20110261T patent/HRP20110261T1/en unknown
- 2011-05-20 CY CY20111100500T patent/CY1112558T1/en unknown
-
2013
- 2013-12-30 US US14/144,292 patent/US20140113935A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NI200900031A (en) | N-METHYLAMINOMETHYL ISOINDOL COMPOSITIONS AND COMPOSITIONS THAT INCLUDE THEM AND METHODS FOR USING THEM. | |
CR9772A (en) | ISOINDOL-IMIDA COMPOUNDS AND COMPOSITIONS THAT INCLUDE IT AND METHODS TO USE THE SAME | |
ECSP10010724A (en) | 5-SUBSTITUTED ISOINDOL COMPOUNDS | |
NI200900170A (en) | SUBSTITUTE ISOINDOLINE 4 '- O - DERIVATIVES AND COMPOSITIONS THAT INCLUDE THEM AND METHODS FOR USING THEM. | |
NI200900040A (en) | 5-SUBSTITUTE QUINAZOLINONE DERIVATIVES AS ANTITUMORAL AGENTS. | |
NI201000041A (en) | DERIVATIVES AND COMPOSITIONS INCLUDING QUINAZOLINONE 6-, 7-, OR 8 - SUBSTITUTE AND METHODS TO USE THE SAME | |
NI201200132A (en) | ARYLMETOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS THAT INCLUDE THEM AND METHODS FOR USING THEM | |
CR10636A (en) | QUINASE INHIBITOR | |
GT200600117A (en) | NEW PHARMACEUTICAL COMPOUNDS | |
NI200900076A (en) | NEW DERIVATIVES OF 1,4-BENZOTHYPINE-1,1-DIOXIDE REPLACED WITH BENZYL RADICALS, A METHOD FOR THEIR PREPARATION, PHARMACEUTICAL PRODUCTS THAT INCLUDE THESE COMPOUNDS AND THEIR USE. | |
UY30498A1 (en) | NEW CLASS OF BENZIMIDAZOLILO COMPOUNDS, ITS SALTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND APPLICATIONS | |
CO6280399A2 (en) | PEPTIDIL NITRILOS AND USE OF THE SAME AS INHIBITORS OF PEPTIDIL PEPTIDASA I | |
CR11518A (en) | CARBAMOIL COMPOUNDS AS DGAT1 190 INHIBITORS | |
CR9851A (en) | TRIAZOLOPIRIDINE DERIVATIVES IN QUALITY OF LIPASE AND PHOSPHOLIPASE INHIBITORS | |
UY30141A1 (en) | NEW POTENTIATING ISOINDOLONES OF METABOTROPIC GLUTAMATE RECEPTORS | |
GT200900292A (en) | "KINASE INHIBITORS P70 S6" | |
CU20090058A7 (en) | PIRAZOLINE COMPOUNDS AND THEIR USE AND PHARMACEUTICAL COMPOSITIONS | |
UY30308A1 (en) | MGLUR5 V MODULATORS | |
AR062211A1 (en) | DERIVATIVES OF 6-CARBOXI-NORMORFINANO. PHARMACEUTICAL COMPOSITIONS | |
EA201171488A1 (en) | LXR MODULATORS | |
ECSP077270A (en) | ACIDS OF TIAZOLO - NAFTILO | |
NI200900052A (en) | HETEROCYCLIC DERIVED FROM METALOPROTEASE INHIBITORS | |
ECSP089019A (en) | TRICYCLIC SULFONAMIDE INHIBITORS, FUSIONED SECRET RANGE | |
UY30307A1 (en) | MGLUR5 VI MODULATORS | |
CR10206A (en) | ACIDS 4-PHENYL-TIAZOL-5-CARBOXYLIC AMIDES OF ACIDS 4-PHENYL-TIAZOL-5-CARBOXYLICS AS INHIBITORS OF THE PLK1 |